Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C7A5 | ISIN: FR0012634822 | Ticker-Symbol: 4RD
München
27.06.25 | 08:02
4,910 Euro
+1,66 % +0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MAAT PHARMA SA Chart 1 Jahr
5-Tage-Chart
MAAT PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
4,7004,86013:03

Aktuelle News zur MAAT PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MAAT PHARMA Aktie jetzt für 0€ handeln
DiMaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting219Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies(MET) dedicated to enhancing...
► Artikel lesen
19.06.MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025249Marketing Authorization application of Xervyteg (MaaT013) in acute graft-versus-host-disease submitted to the European Medicines Agency (EMA) in June 2025 MAA could be expected in H2 2026...
► Artikel lesen
13.06.MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease282Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg Independent dataset from EAP reinforces...
► Artikel lesen
02.06.MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg (MaaT013) in Acute Graft-versus-Host Disease366MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg Xervyteghas...
► Artikel lesen
14.05.MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress292Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. Poster presentation selected...
► Artikel lesen
14.05.MaaT Pharma to Hold Annual General Meeting on June 20, 2025287Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
13.05.MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025302Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall...
► Artikel lesen
12.05.MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)290Regulatory News: MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
29.04.AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology-
28.04.MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034276Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
14.04.Availability of MaaT Pharma's 2024 Universal Registration Document (URD)222Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
08.04.MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT292Following a milestone unblinded interim safety review, the independent Data Safety Monitoring Board (DSMB) has recommended that the study proceed without modification. MaaT033, a pooled...
► Artikel lesen
07.04.MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co422Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
04.04.MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital345Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers) Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage...
► Artikel lesen
31.03.MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies315Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
27.03.MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results836Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year...
► Artikel lesen
19.03.MaaT Pharma stock adds 7% on DSMB nod3
18.03.MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease304The Independent Data Safety and Monitoring Board (DSMB) confirmed the remarkable efficacy results and a positive benefit/risk profile of MaaT013 in this patient population The Company plans...
► Artikel lesen
11.03.MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013467Positive EMA Pediatric Committee opinion has cleared the investigation clinical plan to evaluate the safety and efficacy of MaaT013 in patients from 6 years old to less than 18 years old with...
► Artikel lesen
21.01.MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT481The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceeds as planned without modification. Consistent good safety profile and tolerability for MaaT033...
► Artikel lesen
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1